02181.HK
Mabpharm Limited
HKSE · Healthcare · Biotechnology · CN
HKD 0.43
−1.15%Margins
Gross margin
85.4%
EBITDA margin
12.6%
EBIT margin
4.8%
Net margin
11.1%
FCF margin
2.3%
43.7%
Return on equity
7.3%
Return on assets
7.3%
Return on invested capital
0.66x
Asset turnover
HKD 117.0M
Cash from operations
HKD 0.03
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026